Triple Negative Breast Neoplasms: all 1,163 studies

Page 6 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminatedNCT03829501Phase 1/2Results posted
• AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03800836Phase 1Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
• Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersCompletedNCT03761914Phase 1/2Results posted
• Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant ChemotherapyTerminatedNCT03750240Not applicableResults posted
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT03742102Phase 1/2Results posted
• ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast CancerTerminatedNCT03733119Phase 2Results posted
• MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedNCT03729596Phase 1/2Results posted
• Vaccine-Based Immunotherapy Regimen For NSCLC and TNBCTerminatedNCT03674827Phase 1Results posted
• Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerActive, not recruitingNCT03639948Phase 2Results posted
• Study of ADCT-301 in Patients With Selected Advanced Solid TumorsTerminatedNCT03621982Phase 1Results posted
• Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid TumoursCompletedNCT03620643Phase 2Results posted
• GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03576131Phase 1/2Results posted
• A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyCompletedNCT03542175Phase 1Results posted
• A Study of PF-06873600 in People With CancerTerminatedNCT03519178Phase 1/2Results posted
• A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast CancerCompletedNCT03499899Phase 2Results posted
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerTerminatedNCT03498716Phase 3Results posted
• OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseCompletedNCT03487666Phase 2Results posted
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results posted
• Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)CompletedNCT03396445Phase 1Results posted
• ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial CarcinomaCompletedNCT03394027Phase 2Results posted
• QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedNCT03387085Phase 1/2Results posted
• A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerCompletedNCT03371017Phase 3Results posted
• Breast Cancer Study of Preoperative Pembrolizumab + RadiationActive, not recruitingNCT03366844Phase 1/2Results posted
• Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.CompletedNCT03345485Phase 1/2Results posted
• A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast CancerCompletedNCT03337724Phase 3Results posted
• Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedNCT03333915Phase 1/2Results posted
• To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Active, not recruitingNCT03330847Phase 2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03310957Phase 1/2Results posted
• Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast CancerCompletedNCT03301350Phase 2Results posted
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersCompletedNCT03251378Phase 1Results posted
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT03218826Phase 1Results posted
• Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerCompletedNCT03213041Phase 2Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast CancerCompletedNCT03206203Phase 2Results posted
• Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyTerminatedNCT03199040Phase 1Results posted
• A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast CancerCompletedNCT03197935Phase 3Results posted
• Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.CompletedNCT03197389Early Phase 1Results posted
• TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast CancerCompletedNCT03193853Phase 2Results posted
• Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedNCT03184558Phase 2Results posted
• Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)CompletedNCT03167619Phase 2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)CompletedNCT03125902Phase 3Results posted
• Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast CancerCompletedNCT03121352Phase 2Results posted
• Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerCompletedNCT03106415Phase 1/2Results posted
• Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerCompletedNCT03106077Phase 2Results posted
• A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadCompletedNCT03098550Phase 1/2Results posted
• AVID100 in Advanced Epithelial CarcinomasTerminatedNCT03094169Phase 1/2Results posted
• A Study of AK-01 (LY3295668) in Solid TumorsCompletedNCT03092934Phase 1/2Results posted
• Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)CompletedNCT03057600Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)CompletedNCT03036488Phase 3Results posted
• Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast CancerActive, not recruitingNCT03012100Phase 2Results posted
• SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLCCompletedNCT03004183Phase 2Results posted
• Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast CancerTerminatedNCT02984683Phase 2Results posted
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2Results posted
• Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast CancerCompletedNCT02981303Phase 2Results posted
• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)TerminatedNCT02978716Phase 2Results posted
• Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerCompletedNCT02971761Phase 2Results posted
• Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaActive, not recruitingNCT02957968Phase 2Results posted
• Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)CompletedNCT02950259Phase 1Results posted
• Vaccination of Triple Negative Breast Cancer PatientsCompletedNCT02938442Phase 1/2Results posted
• Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedNCT02898207Phase 1Results posted
• Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerActive, not recruitingNCT02883062Phase 2Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02834403Phase 1/2Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)CompletedNCT02819518Phase 3Results posted
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesCompletedNCT02807844Phase 1/2Results posted
• Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast CancerActive, not recruitingNCT02788981Phase 2Results posted
• Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerCompletedNCT02779855Phase 1/2Results posted
• Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast CancerCompletedNCT02768701Phase 2Results posted
• Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerActive, not recruitingNCT02734290Phase 1/2Results posted
• Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02730130Phase 2Results posted
• Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRTerminatedNCT02720185Phase 2Results posted
• Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast CancerCompletedNCT02719691Phase 1Results posted
• A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)TerminatedNCT02698176Phase 1Results posted
• Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerCompletedNCT02689427Phase 2Results posted
• Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian CancerCompletedNCT02657889Phase 1/2Results posted
• 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT02624700Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)CompletedNCT02622074Phase 1Results posted
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedNCT02595905Phase 2Results posted
• Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCCompletedNCT02593175Phase 2Results posted
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results posted
• Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)CompletedNCT02555657Phase 3Results posted
• Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerCompletedNCT02530489Phase 2Results posted
• Study of Tremelimumab in Patients With Advanced Solid TumorsCompletedNCT02527434Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)CompletedNCT02513472Phase 1/2Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast CancerCompletedNCT02489448Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)CompletedNCT02447003Phase 2Results posted
• Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyActive, not recruitingNCT02445391Phase 3Results posted
• Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)CompletedNCT02435680Phase 2Results posted
• A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)CompletedNCT02425891Phase 3Results posted
• Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation TherapyActive, not recruitingNCT02422498Phase 2Results posted
• Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast CancerCompletedNCT02413320Phase 2Results posted
• Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyActive, not recruitingNCT02411656Phase 2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted

← Triple Negative Breast Neoplasms overview